Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"ZYMEDI","sponsor":"National Heart, Lung, and Blood Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zymedi Announced their Collaboration with the National Heart, Lung, and Blood Institute through a CTA CRADA to Develop ZMA001 mAb, a Potential Treatment for Pulmonary Arterial Hypertension (PAH), a Rare, Female Predominant Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"ZYMEDI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First in Human Dosed in Clinical Trial of ZMA001 for Treatment of Pulmonary Arterial Hypertension (PAH)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by ZYMEDI

    Menu

    ZYMEDI

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              ZYMEDI

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              First in Human Dosed in Clinical Trial of ZMA001 for Treatment of Pulmonary Arterial Hypertension (PAH)

              Details:

              ZMA001 (BC-NKA-20008) is a first-in-class therapeutic antibody targeting the novel pro-inflammatory factor KARS1 that is specific to monocytes and macrophages. It is being evaluated in phase 1 clinical trials for the treatment of pulmonary arterial hypertension.

              Lead Product(s): BC-NKA-20008

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: ZMA001

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 07, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ZYMEDI

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Zymedi Announced their Collaboration with the National Heart, Lung, and Blood Institute through a CTA CRADA to Develop ZMA001 mAb, a Potential Treatment for Pulmonary Arter...

              Details:

              The agreement aims to develop ZMA001, a novel monoclonal antibody targeting pathways thought to play a key role in PAH pathogenesis, for the treatment of pulmonary arterial hypertension (PAH).

              Lead Product(s): ZMA001

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: ZMA001

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: National Heart, Lung, and Blood Institute

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration July 02, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY